Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp ...
Novo Nordisk's Innovative Portfolio and Full Pipeline in Diabetes and Obesity Supports Its Wide Moat
U.S. patents have expired for Novo's three biggest modern insulin therapies NovoLog (2017), NovoMix (2017), and Levemir (2019), but the patent clock is reset with Novo's newer insulin therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback